Dudediligence.

Enliven Therapeutics, Inc

ELVNNASDAQ · Pharmaceutical Preparations
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$69.9M

15 notices · 1,497,791 sh

Apr 29 to Oct 4

Reported ·

$64.7M

53 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

46 of 53 reported sales carry the 10b5-1 box. Together they are 2.20% of the shares on issue.

PLANNED · FORM 144Apr 29 to Oct 4REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-10-01: JEFFREY GARLAND, Form 1442026-09-17: Hohl Benjamin, Form 1442026-09-04: Heyman Richard A., Form 1442026-08-04: Derynck Mika K, Form 1442026-07-17: Collins Helen Louise, Form 1442026-06-22: OrbiMed Genesis Master Fund, L.P., Form 1442026-06-22: OrbiMed Private Investments VII, LP, Form 1442026-06-22: The Biotech Growth Trust PLC, Form 1442026-06-17: Hohl Benjamin, Form 1442026-06-15: The Biotech Growth Trust PLC, Form 1442026-06-15: OrbiMed Private Investments VII, LP, Form 1442026-06-15: OrbiMed Genesis Master Fund, L.P., Form 1442026-06-05: Kunkel Lori Anne, Form 1442026-05-18: Collins Helen Louise, Form 1442026-04-30: Lyssikatos Joseph P, Form 1442025-10-07: Patel Anish, sold2025-10-17: Kintz Samuel, sold2025-10-20: Lyssikatos Joseph P, sold2025-11-07: Patel Anish, sold2025-11-17: Kintz Samuel, sold2025-11-19: Lyssikatos Joseph P, sold2025-12-08: Patel Anish, sold2025-12-19: Lyssikatos Joseph P, sold2026-01-08: Heyman Richard A., sold2026-01-08: Lyssikatos Joseph P, sold2026-01-09: Patel Anish, sold2026-01-20: Heyman Richard A., sold2026-01-20: Lyssikatos Joseph P, sold2026-02-06: Lyssikatos Joseph P, sold2026-02-17: Heyman Richard A., sold2026-02-17: Collins Helen Louise, sold2026-03-06: Hohl Benjamin, sold2026-03-09: Collins Helen Louise, sold2026-03-17: Collins Helen Louise, sold2026-03-25: Collins Helen Louise, sold2026-04-17: Collins Helen Louise, sold2026-05-18: Collins Helen Louise, sold2026-06-05: Kunkel Lori Anne, sold2026-06-15: ORBIMED ADVISORS LLC, sold2026-06-17: Collins Helen Louise, sold2026-06-17: Hohl Benjamin, sold2026-06-22: ORBIMED ADVISORS LLC, sold
under a no plan named▼ salesize is dollars

Form 144 notices, newest first

2026-10-01JEFFREY GARLAND, Director$606,719
13,000 shno plan dateForm 4s on file end Jun 23144 ↗
2026-09-17Hohl Benjamin, CHIEF FINANCIAL OFFICER$591,208
12,036 shplan 2026-03-18Form 4s on file end Jun 23144 ↗
2026-09-04Heyman Richard A., resigned from BOD$2,252,830
38,000 shno plan dateForm 4s on file end Jun 23144 ↗
2026-08-04Derynck Mika K, Director$9,216,462
158,795 shplan 2025-04-08Form 4s on file end Jun 23144 ↗
2026-07-17Collins Helen Louise, CHIEF MEDICAL OFFICER$762,900
15,000 shplan 2025-10-19Form 4s on file end Jun 23144 ↗
2026-06-22OrbiMed Genesis Master Fund, L.P., Shareholder$1,209,805
26,323 shno plan date144 ↗
Form 4, 2026-06-24: sold 860,123 at $45.36 Form 4 ↗
2026-06-22OrbiMed Private Investments VII, LP, Shareholder$38.3M
833,800 shno plan dateForm 4s on file end Jun 23144 ↗
2026-06-22The Biotech Growth Trust PLC, Shareholder$1,430,827
31,132 shno plan dateForm 4s on file end Jun 23144 ↗
2026-06-17Hohl Benjamin, CHIEF FINANCIAL OFFICER$768,198
18,054 shplan 2026-03-18144 ↗
Form 4, 2026-06-22: sold 6,018 at $43.80 Form 4 ↗
2026-06-15The Biotech Growth Trust PLC, Shareholder$433,893
10,243 shno plan dateForm 4s on file end Jun 23144 ↗
2026-06-15OrbiMed Private Investments VII, LP, Shareholder$11.5M
272,322 shno plan date144 ↗
Form 4, 2026-06-17: sold 281,408 at $45.02 Form 4 ↗
2026-06-15OrbiMed Genesis Master Fund, L.P., Shareholder$384,883
9,086 shno plan dateForm 4s on file end Jun 23144 ↗
2026-06-05Kunkel Lori Anne, Board Member$709,800
20,000 shplan 2026-03-06144 ↗
Form 4, 2026-06-09: sold 10,000 at $34.54 Form 4 ↗
2026-05-18Collins Helen Louise, CHIEF MEDICAL OFFICER$620,100
15,000 shplan 2025-10-19144 ↗
Form 4, 2026-05-20: sold 5,000 at $39.79 Form 4 ↗
2026-04-30Lyssikatos Joseph P, CHIEF SCIENTIFIC OFFICER$1,060,000
25,000 shplan 2025-12-30Form 4s on file end Jun 23144 ↗